Price Chart

Executive Summary

XOMA Royalty filed its preliminary proxy statement/prospectus on Form S-4 with the SEC in connection with the proposed acquisition by Ligand Pharmaceuticals. The filing confirms the all-cash deal at $39.00 per share plus one contingent value right (CVR) tied to the Janssen Litigation, with a special stockholder meeting to vote on the merger and holding company reorganization. No changes to deal terms were disclosed; this filing advances the deal toward the expected Q3 2026 close.

Key Financial Metrics

Key Facts

• Ligand to acquire XOMA Royalty for $39.00 per share in cash plus one CVR per share tied to the Janssen Litigation
• Deal valued at approximately $739 million for the cash portion
• Special stockholder meeting to be held to vote on merger and holding company reorganization
• BVF Partners, holding ~43.3% of XOMA common stock, has agreed to vote in favor via Support Agreements
• Perpetual Preferred Stock (Series A and B) to be redeemed prior to closing
• Closing expected in Q3 2026, subject to stockholder and HSR approvals
• Termination fee of $40.0 million payable by XOMA under certain circumstances

Financial Impact

$39.00 per share cash consideration plus CVR; total cash consideration ~$739M based on ~18.9M fully diluted shares

Risk Factors

• Stockholder approval still required, though BVF's 43.3% support makes failure unlikely
• HSR waiting period must expire or be terminated
• Janssen Litigation may yield no recovery, making CVRs worthless
• Litigation challenging the merger could delay or prevent closing
• If deal fails, XOMA must pay $40M termination fee and faces operational uncertainty

Market Snapshot

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

US Market Status

Related Tickers